Prelude Shares Jump as Incyte Drops Rival JAK2 Drug
Prelude Therapeutics stock rises after Incyte discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal.
/ 3 items
#PRLD↓
Prelude Therapeutics Gets FDA Green Light for Groundbreaking Blood Cancer Treatment
Prelude Therapeutics receives FDA clearance to begin testing PRT12396, a targeted therapy for myeloproliferative neoplasms affecting thousands of patients.
Prelude Therapeutics Refocuses Strategy to Advance Key Cancer Programs
Prelude Therapeutics streamlines its oncology pipeline — prioritizing JAK2V617F and KAT6A programs, pausing SMARCA2, and securing major funding through an Incyte partnership.